We are reading about the FDA PDUFA change, complex obesity medicine

To you morning normal, and it is good. The clean, blue sky and comfortable winds are wrapped in a comfortable campus, a short person sleeping, and the official mascot is threatening to maintain the street by local cats. As for us, we are engaged in ordinary rituals -we can brew a cup of coffee by launching a coffee kettle (today’s choice is the Pikan Burnburn) and get an interesting item. According to the memo, there are several idiots that will help you start your trip today. We hope to be meaningful and productive. Meanwhile, we enjoy secret documents and wet tips. …

NOOM, an online weight loss company, has begun to provide a small amount of WEGOVY composite version of Novo Nordisk for the mass production of custom medicine.,,, Reuters It tells us. NOOM said that it will provide a composite semi -glue tide version, an active ingredient of Wegovy and Diabetes Drug Ozempic as part of a personalized program for the patient, which will comply with the change of FDA regulations. Taking a small amount of weight loss drug, sometimes a small amount of weight loss drugs, sometimes gained popularity due to high cost and side effects. Hundreds of less than the name brand drugs can approach the doctor and pharmacy production version based on Semi Glutite or Tir J. Pate, which are the main components of Eli Lily’s rival Jeff Bound and Machun. NOOM offers a composite semagluide at a starting price of $ 149 per first month. According to the NOVO and LILLY websites, the price of 2.5 millimeter Wegovy or Zepbound is $ 349.

The FDA is looking for the possibility of changing the fee structure of the prescription drug user fee.According to Regulation focus. “If we look at the next re -certification, it is time to think about whether the fee structure and the amount are unintended. When submitting the application form, the company’s perception of the company that passes millions of dollars can help some Americans can question the results of the review, how to structurally, and how to structure them. The advantage of the upcoming re -approval, ”said Grace Graham, a newly named policy, legislative and international business deputy director, at the Food and Drug Law Research Institute. The FDA will hold two open meetings in July and discuss the re-certification of the 2028-2032 fiscal year. The current legislative authority for this program expires at the end of September 2027.